Thrombosis最新文献_第9页

Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies. 猪和犬 von Willebrand 因子和 von Willebrand 病：止血、血栓形成和动脉粥样硬化研究。

Thrombosis Pub Date : 2010-01-01 Epub Date: 2011-02-07 DOI: 10.1155/2010/461238

Timothy C Nichols, Dwight A Bellinger, Elizabeth P Merricks, Robin A Raymer, Mark T Kloos, Natalie Defriess, Margaret V Ragni, Thomas R Griggs

{"title":"Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.","authors":"Timothy C Nichols, Dwight A Bellinger, Elizabeth P Merricks, Robin A Raymer, Mark T Kloos, Natalie Defriess, Margaret V Ragni, Thomas R Griggs","doi":"10.1155/2010/461238","DOIUrl":"10.1155/2010/461238","url":null,"abstract":"Use of animal models of inherited and induced von Willebrand factor (VWF) deficiency continues to advance the knowledge of VWF-related diseases: von Willebrand disease (VWD), thrombotic thrombocytopenic purpura (TTP), and coronary artery thrombosis. First, in humans, pigs, and dogs, VWF is essential for normal hemostasis; without VWF bleeding events are severe and can be fatal. Second, the ADAMTS13 cleavage site is preserved in all three species suggesting all use this mechanism for normal VWF multimer processing and that all are susceptible to TTP when ADAMTS13 function is reduced. Third, while the role of VWF in atherogenesis is debated, arterial thrombosis complicating atherosclerosis appears to be VWF-dependent. The differences in the VWF gene and protein between humans, pigs, and dogs are relatively few but important to consider in the design of VWF-focused experiments. These homologies and differences are reviewed in detail and their implications for research projects are discussed. The current status of porcine and canine VWD are also reviewed as well as their potential role in future studies of VWF-related disorders of hemostasis and thrombosis.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2010 ","pages":"461238"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9560793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. 特发性静脉血栓栓塞后不同的有限抗凝时间和结果:一项荟萃分析。

Thrombosis Pub Date : 2010-01-01 Epub Date: 2010-12-29 DOI: 10.1155/2010/540386

Aaron B Holley, Christopher S King, Jeffrey L Jackson, Lisa K Moores

{"title":"Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis.","authors":"Aaron B Holley, Christopher S King, Jeffrey L Jackson, Lisa K Moores","doi":"10.1155/2010/540386","DOIUrl":"https://doi.org/10.1155/2010/540386","url":null,"abstract":"Unlabelled: Introduction. Controversy remains over the optimal length of anticoagulation following idiopathic venous thromboembolism. We sought to determine if a longer, finite course of anticoagulation offered additional benefit over a short course in the initial treatment of the first episode of idiopathic venous thromboembolism. Data Extraction. Rates of deep venous thrombosis, pulmonary embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling patients with first time, idiopathic venous thromboembolism. Data was pooled using random effects meta-regression. Results. Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy was stopped, recurrent venous thromboembolism (0.03 (95% CI: -0.28 to 0.35); P = .24), mortality (-0.10 (95% CI: -0.24 to 0.04); P = .15), and major bleeding (-0.01 (95% CI: -0.05 to 0.02); P = .44) rates measured in percent per patient years, did not significantly change.Conclusions: Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6 months of secondary prophylaxis with vitamin K antagonists. At that time, a decision between continuing with indefinite therapy can be made, but there is no benefit to a longer (but finite) course of therapy.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":" ","pages":"540386"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/540386","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30254942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery. 简化血栓预防可改善骨科手术的疗效。

Thrombosis Pub Date : 2010-01-01 Epub Date: 2010-09-13 DOI: 10.1155/2010/108049

Richard J Friedman

引用次数: 0

New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. 用于择期全髋关节和膝关节置换术后血栓预防的新型口服抗凝剂。

Thrombosis Pub Date : 2010-01-01 Epub Date: 2010-07-29 DOI: 10.1155/2010/280731

Richard J Friedman

引用次数: 0